Citi analyst Mathieu Chevrier maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$345.00. The company’s shares closed last Tuesday at $191.59.
Citi analyst Mathieu Chevrier maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$345.00. The company’s shares closed last Tuesday at $191.59.
Accumulus Synergy and its Founding Sponsors are proud to welcome CSL as its first member organization. This collaboration marks significant progress in collectively bringing together industry stakeholders to advance the
CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that Japan’s Ministry of Health, Labor and Welfare, or MHLW, granted approval and authorization for their updated self-amplifying mRNA COVID-19 vaccine, Kostaive. The
In a report released yesterday, Shane Storey from Wilsons maintained a Hold rating on CSL (CMXHF – Research Report), with a price target of A$291.78. The company’s shares closed today
In a report released yesterday, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$329.62. The company’s shares closed yesterday